Fact-checked by Grok 2 weeks ago

Steroidogenic enzyme

Steroidogenic enzymes are specialized proteins that catalyze the biochemical transformation of into hormones, including glucocorticoids, mineralocorticoids, androgens, estrogens, and progestogens, through a series of oxidation, , reduction, and reactions. These enzymes are essential for steroidogenesis, the process that occurs primarily in endocrine tissues such as the adrenal glands, gonads, and , as well as in extraglandular sites like the , , and immune cells. They enable the production of hormones critical for regulating , , stress responses, electrolyte balance, and immune function. The primary classes of steroidogenic enzymes consist of cytochrome P450 (CYP) enzymes and hydroxysteroid dehydrogenases (HSDs), with the (StAR) supporting the initial transport step. CYP enzymes, divided into mitochondrial type 1 (e.g., CYP11A1, also called P450scc, CYP11B1, and CYP11B2) and endoplasmic reticulum type 2 (e.g., , CYP21A2, and CYP19A1), perform key reactions such as side-chain cleavage of to —the rate-limiting first step—and subsequent hydroxylations or to form precursors for specific hormones like , aldosterone, and . HSD enzymes, belonging to the short-chain dehydrogenase/reductase (SDR) or aldo-keto reductase (AKR) families (e.g., 3β-HSD types 1 and 2, 17β-HSD types 1–5, and 11β-HSD types 1 and 2), facilitate the interconversion of steroid intermediates, such as transforming Δ5-3β-hydroxysteroids to Δ4-3-ketosteroids or reducing to testosterone. Steroidogenic enzymes are compartmentalized within cells, with mitochondrial localization for initial CYP reactions and or cytosolic sites for HSDs and later CYPs, ensuring efficient substrate flow. Their expression and activity are regulated by hormonal signals, including (ACTH) for adrenals and / (LH/FSH) for gonads, which activate cAMP-dependent pathways and transcription factors like steroidogenic factor-1 (SF-1). Additional cofactors, such as NADPH, , and P450 oxidoreductase (POR), are required for in CYP . These enzymes underpin vital physiological processes: glucocorticoids like mediate stress and ; mineralocorticoids like aldosterone maintain sodium-potassium balance; and sex steroids drive , , and . Disruptions, often due to genetic , result in disorders such as (CAH)—most commonly from CYP21A2 deficiency—affecting up to 1 in 15,000 births and causing deficiency with excess, or StAR leading to lipoid CAH with severe loss. Recent research also highlights their role in local production within immune cells, influencing and .

Introduction

Definition and Types

Steroidogenic enzymes are a specialized class of enzymes that catalyze the biosynthetic conversion of cholesterol into biologically active steroid hormones, encompassing sex steroids such as androgens, estrogens, and progestogens; corticosteroids including glucocorticoids and mineralocorticoids; and neurosteroids that modulate neuronal activity. These enzymes facilitate a series of oxidative and reductive reactions essential for steroid hormone production in various tissues, including the adrenal glands, gonads, and brain. The primary types of steroidogenic enzymes are (CYP) monooxygenases and hydroxysteroid dehydrogenases (HSDs). CYP enzymes, which constitute the majority of steroidogenic catalysts, perform , side-chain cleavage, and reactions critical for scaffold formation. In contrast, HSDs mediate oxidation-reduction reactions that interconvert active and inactive forms, such as ketosteroids and hydroxysteroids. Structurally, CYP enzymes are heme-containing oxidases featuring a conserved cysteine ligand to the heme iron, enabling them to absorb light at 450 nm and require NADPH and molecular oxygen as cofactors for monooxygenation. They are subdivided into type 1 (mitochondrial, reliant on ferredoxin for electron transfer) and type 2 (endoplasmic reticulum-localized, using P450 oxidoreductase). HSDs, belonging to the short-chain dehydrogenase/reductase (SDR) or aldo-keto reductase (AKR) superfamilies, are typically 35–45 kDa proteins without heme; they depend on NAD(P)+/NAD(P)H cofactors and exhibit a Rossmann fold (SDR) or TIM-barrel structure (AKR) to facilitate hydride transfer. Evolutionarily, steroidogenic enzymes derive from ancient families, with CYP and HSD orthologs exhibiting high sequence conservation across s, reflecting their essential role in signaling that emerged early in lineage diversification. This conservation underscores adaptations from precursors, where related CYPs handled before specializing in steroidogenesis in s.

Biological Significance

Steroidogenic enzymes are predominantly expressed in specialized endocrine tissues, where they facilitate the of hormones essential for various physiological processes. High levels of expression occur in the , gonads (including testes and ovaries), and , enabling the production of glucocorticoids, mineralocorticoids, and sex steroids in these primary sites. Lower expression is observed in peripheral tissues such as the and , supporting localized steroid production and ; for instance, neurosteroids are synthesized in the via enzymes like P450scc and 3β-HSD, while the utilizes isoforms such as HSD3B1 and AKR1C3 to convert precursors like DHEA into active androgens. These enzymes play crucial roles in maintaining , , and responses by enabling the of key hormones. In the adrenal glands, they produce , which regulates , immune function, and the response through ACTH-mediated pathways, and aldosterone, which controls balance and via the renin-angiotensin system. In the gonads, enzymes such as P450c17 and 17β-HSD3 generate testosterone and , supporting reproductive functions, , and the development of secondary sex characteristics. Additionally, placental steroidogenesis, driven by enzymes like P450scc and 3β-HSD, produces progesterone to maintain by promoting uterine quiescence and inhibiting contractions. Estrogens are produced via P450arom from precursor androgens. The enzymes are vital for developmental processes, particularly in fetal maturation of the adrenal and gonadal systems. They contribute to during embryogenesis; for example, synthesis via gonadal enzymes determines male genital , while disruptions can lead to . Fetal adrenal production, facilitated by enzymes like P450c11β, also supports maturation and metabolic adaptation in preparation for birth. Across species, steroidogenic pathways exhibit conservation in mammals but with notable variations in isoforms and expression. Humans primarily utilize the Δ5 pathway for adrenal production, whereas produce instead of due to differences in P450c17 expression and rely on distinct isozymes. Regarding hydroxysteroid dehydrogenases (HSDs), humans express two 3β-HSD isozymes (HSD3B1 and HSD3B2), while mice have six isoforms, reflecting adaptations in that influence research models for human disorders.

Steroidogenic Pathway

Overview of Steroidogenesis

Steroidogenesis is the multistep biochemical process by which cholesterol serves as the precursor for the synthesis of all steroid hormones, occurring in specialized tissues such as the adrenal glands, gonads, and placenta. Cholesterol is sourced primarily from the cellular uptake of low-density lipoprotein (LDL) particles or from de novo synthesis via the mevalonate pathway within steroidogenic cells. The initial and rate-limiting step involves the translocation of free cholesterol from intracellular lipid droplets or the outer mitochondrial membrane to the inner mitochondrial membrane, facilitated by the Steroidogenic Acute Regulatory (StAR) protein, which functions as a transport mediator rather than an enzyme. In the mitochondria, cholesterol undergoes conversion to pregnenolone, establishing this molecule as the universal precursor for subsequent steroid transformations. Following the mitochondrial phase, is shuttled to the smooth for further processing through sequential oxidation and reactions, leading to branched pathways that yield distinct classes. In the , synthesis is zonally organized: the outer pathway produces mineralocorticoids to regulate balance, the middle generates glucocorticoids for metabolic , and the inner zona reticularis forms precursors that contribute to gonadal production. The gonads exhibit tissue-specific variations, with ovarian cells favoring biosynthesis and testicular cells prioritizing such as testosterone. During , the becomes a prominent site of steroidogenesis, synthesizing progesterone to maintain uterine quiescence and support fetal development. This compartmentalized process relies on multi-step oxidations, with the overall varying by end product but generally requiring 3–11 molecules each of molecular oxygen (O₂) and the NADPH per molecule synthesized, reflecting the number of oxygen-dependent and cleavage events. serves as the pivotal , enabling a conceptual linear progression from to , then to progesterone as a key branching point, and ultimately to bioactive hormones tailored to physiological needs.

Major Enzymes and Reactions

Steroidogenesis involves a series of enzymatic reactions that transform into various steroid hormones, with key enzymes including monooxygenases and hydroxysteroid dehydrogenases. These enzymes are compartmentalized within cells, primarily in the mitochondria for the initial steps and the (ER) for subsequent transformations, and they typically require NADPH and molecular oxygen as cofactors for oxidative reactions. The pathway branches to produce glucocorticoids, mineralocorticoids, androgens, and estrogens, with each enzyme catalyzing specific hydroxylations, cleavages, or isomerizations. The first and rate-limiting step is catalyzed by CYP11A1 (, EC 1.14.15.6), a mitochondrial that converts to through three sequential monooxygenations, cleaving the C20-C22 bond. The overall reaction is: + 3 O₂ + 3 NADPH + 3 H⁺ → + isocaproaldehyde + 3 NADP⁺ + 4 H₂O, requiring adrenodoxin and adrenodoxin reductase as electron donors. In humans, CYP11A1 exists as a single isoform and is expressed predominantly in the , gonads, and . Following this, enzymes, specifically the isoforms HSD3B1 (type 1, EC 1.1.1.145) and HSD3B2 (type 2, EC 1.1.1.145), catalyze the oxidation and isomerization of Δ⁵-3β-hydroxysteroids to Δ⁴-3-ketosteroids, such as converting to progesterone. The reaction is: + NAD⁺ → progesterone + NADH + H⁺, utilizing NAD⁺ as a cofactor and occurring in both mitochondrial and compartments. HSD3B1 is expressed in peripheral tissues and , while HSD3B2 predominates in the adrenal glands and gonads. CYP17A1 (17α-hydroxylase/17,20-lyase, EC 1.14.99.9) is an ER-localized enzyme with dual activities: 17α-hydroxylation of or progesterone, followed by side-chain cleavage to produce Δ¹⁶ steroids like dehydroepiandrosterone (DHEA) from 17α-hydroxypregnenolone. The reactions are: + O₂ + NADPH + H⁺ → 17α-hydroxypregnenolone + H₂O, and then 17α-hydroxypregnenolone + O₂ + NADPH + H⁺ → DHEA + acetic acid + H₂O; cytochrome b5 enhances the lyase activity, and the enzyme requires NADPH, O₂, and . Humans express a single isoform, primarily in the adrenal zona reticularis and fasciculata, as well as in gonads. In the and branches, CYP21A2 (, EC 1.14.99.10) performs 21-hydroxylation in the , converting progesterone to or 17α-hydroxyprogesterone to . The reaction is: progesterone + O₂ + NADPH + H⁺ → + H₂O, with NADPH, O₂, and as cofactors. This enzyme has a single functional isoform in humans and is expressed in the adrenal and glomerulosa. Subsequent mitochondrial steps involve CYP11B1 (11β-hydroxylase, EC 1.14.15.4), which hydroxylates to in the adrenal . The reaction is: + O₂ + reduced adrenodoxin + H⁺ → + oxidized adrenodoxin + H₂O, utilizing NADPH, O₂, adrenodoxin, and adrenodoxin reductase. Humans have a single CYP11B1 isoform. Similarly, CYP11B2 (aldosterone synthase, EC 1.14.15.5) in the adrenal catalyzes three reactions—11β-hydroxylation, 18-hydroxylation, and 18-oxidation—to convert to aldosterone via intermediates like and 18-hydroxycorticosterone. The overall process requires NADPH, O₂, adrenodoxin, and adrenodoxin reductase, with a single human isoform. For estrogen biosynthesis, CYP19A1 (, EC ) is an ER enzyme that catalyzes the aromatization of androgens to through three successive oxidations, such as to estrone or testosterone to . The reaction is: + 3 O₂ + 3 NADPH + 3 H⁺ → estrone + 3 NADP⁺ + 3 H₂O + , requiring NADPH, O₂, and . In humans, CYP19A1 is encoded by a single with tissue-specific promoters, leading to expression in ovaries, , , , and . 17β-hydroxysteroid dehydrogenase (17β-HSD) enzymes, a family of isoforms, interconvert active 17β-hydroxy steroids and their 17-keto precursors in the final steps of androgen and estrogen synthesis. For example, HSD17B1 (type 1, EC 1.1.1.62) reduces estrone to estradiol using NADPH, while HSD17B3 (type 3, EC 1.1.1.62) reduces androstenedione to testosterone in the testis; the general reaction is: estrone + NADPH + H⁺ → estradiol + NADP⁺. These enzymes are localized in the cytosol (e.g., type 1) or ER (e.g., types 3, 5), with multiple isoforms including HSD17B1 (placenta, ovary), HSD17B2 (endometrium, placenta), HSD17B3 (testis), and HSD17B5/AKR1C3 (adrenal, peripheral tissues). Finally, 5α-reductase enzymes (SRD5A1 type 1, EC 1.3.99.5; SRD5A2 type 2, EC 1.3.99.5) reduce the Δ⁴-5 double bond in testosterone to form the more potent androgen dihydrotestosterone (DHT) in target tissues. The reaction is: testosterone + NADPH + H⁺ → 5α-dihydrotestosterone + NADP⁺, occurring in the ER and requiring NADPH. SRD5A1 is expressed in the liver, skin, and scalp, while SRD5A2 predominates in the prostate, genital skin, and male reproductive tissues; a type 3 isoform (SRD5A3) is also present in the prostate and brain.

Regulation

Acute and Hormonal Control

The acute regulation of steroidogenesis is primarily mediated by trophic hormones that rapidly activate signaling pathways to enhance availability for synthesis. In the adrenal glands, (ACTH) binds to G-protein-coupled receptors on cells, stimulating adenylate cyclase to increase intracellular () levels. Similarly, in the gonads, (LH) and (FSH) act on theca and granulosa cells, respectively, via the same receptor mechanism to elevate . This surge activates protein kinase A (PKA), which phosphorylates key proteins, including the steroidogenic acute regulatory () protein at serine 195 () or serine 194 (), facilitating rapid delivery from cytosolic sources to the mitochondrial inner membrane where side-chain cleavage enzyme (CYP11A1) resides. These post-translational modifications enable steroid production within minutes, bypassing the need for new protein synthesis in the initial phase. In the adrenal , aldosterone synthesis follows a distinct pathway independent of . II binds to its receptors, triggering activation, production, and calcium (Ca²⁺) influx, which stimulates and enhances activity without involving or . This Ca²⁺-dependent mechanism ensures rapid responses to hemodynamic signals, increasing flux to CYP11A1 specifically for production. The rate-limiting step in acute steroidogenesis is the StAR-mediated transfer of to CYP11A1, which can be induced within minutes of stimulation, leading to a sharp increase in steroid output. StAR's short , approximately 14-16 minutes in steroidogenic cells, allows for precise temporal control, as the protein is rapidly degraded post-activation to prevent sustained overproduction. mechanisms maintain : directly inhibits ACTH secretion at the pituitary and hypothalamic levels via receptors, reducing further stimulation. In the gonadal axis, rising and progesterone exert on (GnRH) neurons in the , suppressing LH/FSH release to modulate ovarian steroidogenesis. Illustrative examples highlight the speed of these controls. ACTH infusion in elicits maximal (corticosterone) production between 5 and 15 minutes, reflecting swift activation and mobilization. Likewise, the preovulatory LH surge triggers within 24-36 hours and initiates a rapid progesterone rise from the shortly thereafter, supporting maintenance.

Chronic Regulation and Gene Expression

Chronic regulation of steroidogenic enzymes occurs primarily through transcriptional and epigenetic mechanisms that modulate over extended periods, establishing baseline levels of enzyme production in steroidogenic tissues such as the adrenal glands and gonads. Key transcription factors, including steroidogenic factor-1 (SF-1, encoded by NR5A1) and dosage-sensitive sex reversal, adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (DAX-1, encoded by NR0B1), act as master regulators by binding to promoter regions of multiple steroidogenic . SF-1 binds to specific elements in the promoters of like CYP11A1 (encoding ) and HSD3B2 (encoding type 2), thereby activating their transcription and coordinating . DAX-1, in contrast, functions as a corepressor by interacting with SF-1 to inhibit its activity, thereby fine-tuning expression of these in a tissue- and context-dependent manner. Hormone-responsive elements further contribute to chronic regulation by integrating endocrine signals into gene expression programs. Glucocorticoid receptors (GRs) can induce or repress target genes, such as CYP11B1 (encoding 11β-hydroxylase), through mechanisms that limit excessive production; for instance, activated GRs interact with other factors to suppress ACTH-stimulated transcription of CYP11B1 in adrenocortical cells. Similarly, cAMP response element-binding protein (CREB), activated via sustained signaling, binds to cAMP-responsive elements in the promoters of (steroidogenic acute regulatory protein) and CYP11A1, promoting their long-term expression and supporting ongoing cholesterol transport and steroidogenesis. These elements ensure adaptive responses to hormonal cues, maintaining physiological steroid levels without the rapid dynamics of acute signaling. Epigenetic modifications provide an additional layer of control, silencing or activating steroidogenic genes in a tissue-specific fashion. typically represses by adding methyl groups to CpG islands in promoter regions, thereby silencing steroidogenic genes like and CYP19A1 in non-steroidogenic tissues; for example, hypermethylation of the promoter in non-adrenal cells prevents . In contrast, , facilitated by coactivators such as CBP/p300, promotes accessibility and enhances transcription in adrenals and gonads; treatment with inhibitors or stimulation increases acetylation of H3 and H4 at the promoter, boosting its expression in Leydig cells. Developmental regulation underscores the critical role of these mechanisms in establishing steroidogenic competence. Targeted knockout of SF-1 in mice results in complete of the adrenal glands and gonads, highlighting its indispensable function in their formation and subsequent enzyme expression. In humans, heterozygous or homozygous mutations in NR5A1, such as p.G35E or p.R92Q, disrupt SF-1 function and cause , often accompanied by impaired gonadal development and reduced steroidogenic capacity. Tissue-specific promoters enable differential expression of steroidogenic enzymes across organs. For (encoding 17α-hydroxylase/17,20-lyase), alternative promoter usage and regulatory elements lead to distinct transcriptional profiles in adrenals versus gonads; in the adrenal /reticularis, specific enhancers drive expression for and synthesis, while gonadal promoters favor sex steroid production under influence. This promoter diversity ensures appropriate enzyme levels tailored to local physiological demands.

Clinical Aspects

Disorders from Enzyme Deficiencies

Disorders arising from deficiencies in steroidogenic enzymes primarily manifest as (CAH), a group of autosomal recessive conditions that impair adrenal steroidogenesis. CAH due to 21-hydroxylase (CYP21A2) deficiency is the most prevalent form, accounting for 90% to 95% of all cases. This enzyme catalyzes the conversion of progesterone to deoxycorticosterone and 17-hydroxyprogesterone to in the and pathways. Its deficiency results in reduced and aldosterone production, leading to with salt wasting, , and in severe cases, alongside excess causing in females and in males. The condition has an incidence of approximately 1 in 15,000 live births in White populations. Other enzyme deficiencies contribute to rarer CAH variants. Mutations in the cause lipoid CAH, the most severe form of CAH, characterized by profound impairment of all synthesis due to defective transport into mitochondria, resulting in life-threatening salt wasting, , and gonadal dysfunction from early infancy. Mutations in cause a rarer, similar . 3β-Hydroxysteroid dehydrogenase type 2 (3β-HSD2) deficiency leads to salt-losing CAH with incomplete and synthesis; affected 46,XY individuals often present with ambiguous genitalia due to impaired production, while females may show mild . 17α-Hydroxylase/17,20-lyase (CYP17A1) deficiency disrupts and sex steroid synthesis, causing from excess s and (DSD) in both 46,XX (primary amenorrhea, lack of secondary sex characteristics) and 46,XY (female external genitalia or ambiguous features) individuals. Less common disorders include 11β-hydroxylase (CYP11B1) deficiency, which accounts for 5% to 8% of CAH cases and features from excess alongside and due to deoxycorticosterone accumulation. Aromatase (CYP19A1) deficiency, a non-adrenal steroidogenic defect, results in excess and low estrogens, leading to maternal during pregnancy (, ) and, in affected females, ambiguous genitalia at birth, polycystic ovaries, and with primary amenorrhea. The of these deficiencies involves enzymatic blocks in the steroidogenic pathway, which divert precursors into alternative routes and provoke compensatory adrenal via elevated ACTH. For instance, in CYP21A2 deficiency, the block at the 21-hydroxylation step causes buildup of 17-hydroxyprogesterone, which is shunted toward biosynthesis, exacerbating . Similar shunting occurs in other deficiencies, such as excess deoxycorticosterone in CYP11B1 defects, contributing to . Diagnosis of CAH, particularly deficiency, relies on programs that measure elevated 17-hydroxyprogesterone levels in blood spots, enabling early detection and prevention of crises. Genetic analysis reveals that most CYP21A2 mutations arise from unequal recombination or gene conversions with the adjacent non-functional pseudogene CYP21A1P, leading to deleterious variants like large deletions or point mutations. Prevalence varies by ethnicity, with higher rates in certain populations due to founder effects.

Therapeutic Targeting and Inhibitors

Steroidogenic enzymes are key targets for pharmacological interventions in endocrine disorders and hormone-dependent cancers, where modulating their activity can normalize hormone levels or suppress pathological signaling. Inhibitors of these enzymes, particularly family members, have been developed to block steroid biosynthesis at specific steps, offering symptomatic relief or tumor control. For instance, acts as a broad-spectrum inhibitor of multiple CYP enzymes, including , CYP11A1, and CYP11B1, and is used off-label to reduce production in by disrupting adrenal steroidogenesis. Similarly, specifically inhibits 11β-hydroxylase (CYP11B1), preventing the conversion of to , and has shown efficacy in normalizing biochemical parameters in patients with due to adrenal tumors or ectopic ACTH production. In oncology, selective inhibitors target androgen or estrogen synthesis to deprive hormone-responsive tumors of growth stimuli. Abiraterone acetate, a potent CYP17A1 inhibitor, blocks the conversion of pregnenolone and progesterone to downstream androgens, effectively suppressing intratumoral androgen production in castration-resistant prostate cancer; it was approved by the FDA in 2011 based on phase III trial data demonstrating improved survival when combined with prednisone. Aromatase inhibitors like anastrozole and letrozole inhibit CYP19A1, reducing the aromatization of androgens to estrogens, and are standard adjuvant therapies for postmenopausal women with estrogen receptor-positive breast cancer, with letrozole showing superior estrogen suppression compared to anastrozole in clinical studies. Additionally, 5α-reductase inhibitors such as finasteride (type 2 selective) and dutasteride (dual type 1 and 2) prevent the conversion of testosterone to dihydrotestosterone (DHT), alleviating symptoms of benign prostatic hyperplasia (BPH) by reducing prostate volume and lowering the risk of acute urinary retention, while also demonstrating chemopreventive effects against prostate cancer in long-term trials. Emerging gene therapies aim to address root causes of steroidogenic enzyme deficiencies, such as in congenital adrenal hyperplasia (CAH), by delivering functional enzyme genes via adeno-associated virus (AAV) vectors to restore steroidogenesis. Preclinical studies in mouse models of 21-hydroxylase deficiency have shown AAV-mediated expression of CYP21A2 can normalize cortisol production, but challenges include limited transduction efficiency in adrenal cells, transient expression due to vector limitations, and off-target effects from immune responses or packaging constraints. A phase 1/2 trial of the AAV5 vector BBP-631 for 21-hydroxylase enzyme replacement in adults with classic CAH was completed, but development was discontinued in September 2024 due to the therapy not achieving sufficient efficacy in sustainably increasing cortisol production, although dose-dependent improvements were observed; as of November 2025, the company is seeking partners for potential further development. Other gene therapy approaches for CAH remain in preclinical stages. Therapeutic targeting is not without risks, as enzyme inhibition can lead to hormonal imbalances requiring supportive care. For example, blockade with abiraterone induces hypoandrogenism, manifesting as fatigue, hot flushes, and , while also causing excess through precursor accumulation, resulting in and that necessitate co-administration of glucocorticoids like to mitigate ACTH-driven effects. Broad inhibitors like carry risks, limiting long-term use, whereas inhibitors may increase the detection of high-grade prostate cancers due to prostate volume reduction. These side effects underscore the need for monitoring and personalized dosing in clinical management.

References

  1. [1]
    https://doi.org/10.1210/er.2010-0013
  2. [2]
    The Regulation of Steroid Action by Sulfation and Desulfation
    Sulfation and desulfation are vital biological processes that regulate steroidogenesis and thus, steroid hormone action in a variety of tissue (Figure 1).
  3. [3]
    Evolution of Retinoid and Steroid Signaling: Vertebrate ...
    Similar to retinoid metabolism, steroidogenesis (fig. 1B) is also a complex biochemical pathway that involves numerous cytochrome P450 (Cyp) and hydroxysteroid ...
  4. [4]
    Independent elaboration of steroid hormone signaling pathways in ...
    Our analysis reveals that steroidogenesis has been independently elaborated in the 3 main bilaterian lineages, and that steroidogenic cytochrome P450 enzymes ...
  5. [5]
    The Molecular Biology, Biochemistry, and Physiology of ... - PMC - NIH
    Steroidogenic enzymes fall into two groups: cytochrome P450 enzymes and hydroxysteroid dehydrogenases. A cytochrome P450 may be either type 1 (in ...
  6. [6]
    Human steroid biosynthesis, metabolism and excretion are ... - PMC
    The function of the HSD enzymes from both families is to catalyze the conversion of a given hydroxysteroid to its corresponding ketosteroid counterpart and ...
  7. [7]
    Regulation of 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase
    In humans, there are two 3β-HSD isozymes encoded by the HSD3B1 and HSD3B2 genes. In mice, six 3β-HSD isozymes have been found [27], and in rats, two isoforms ...
  8. [8]
    EC 1.14.15.6 - IUBMB Nomenclature
    EC 1.14.15.6 · Reaction: cholesterol + 6 reduced adrenodoxin + 3 O2 + 6 H+ = pregnenolone + 4-methylpentanal + 6 oxidized adrenodoxin + 4 H2O (overall reaction)Missing: equation | Show results with:equation
  9. [9]
    EC 1.1.1.145 - ExplorEnz
    EC 1.1.1.145. Accepted name: 3β-hydroxy-Δ5-steroid dehydrogenase. Reaction: a 3β-hydroxy-Δ5-steroid + NAD+ = a 3-oxo-Δ5-steroid + NADH + H+.
  10. [10]
    Current knowledge on the acute regulation of steroidogenesis - PMC
    The acute regulation of steroidogenesis in the adrenal and gonads is controlled by cholesterol transfer into the mitochondria and this review covers two decades ...
  11. [11]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6044331/
  12. [12]
    https://pubmed.ncbi.nlm.nih.gov/7961770/
  13. [13]
    The active form of the steroidogenic acute regulatory protein, StAR ...
    ... steroidogenic cells that is synthesized rapidly in response to cAMP and has a very short half-life (14–16). StAR rapidly increases the movement of ...
  14. [14]
    Physiology, Adrenocorticotropic Hormone (ACTH) - StatPearls - NCBI
    An ACTH stimulation is a confirmatory test. Exogenous ACTH is administrated while measuring the levels of serum cortisol before administration and 30 minutes ...
  15. [15]
    Physiology of GnRH and Gonadotrophin Secretion - Endotext - NCBI
    Oct 15, 2024 · Literature to date suggests that there is dual-site sex-steroid feedback in the regulation of gonadotropin secretion, occurring at the level of ...
  16. [16]
    Temporal Effect of Adrenocorticotrophic Hormone on Adrenal ...
    Nov 16, 2010 · ACTH produced rapid and transient increases in plasma corticosterone, with maximal responses between 5 and 15 min, and a decrease to almost ...Analysis Of Adrenal Glands · Results · Effect Of Acth Injection On...
  17. [17]
    Am I Ovulating? patient education fact sheet | ReproductiveFacts.org
    Ovulation is spontaneously triggered about 36-40 hours after blood levels of a hormone called luteinizing hormone (LH) rise. This is called the LH surge. Once ...
  18. [18]
    Frontiers | Impact of ACTH Signaling on Transcriptional Regulation of Steroidogenic Genes
    Summary of each segment:
  19. [19]
    Autocrine positive regulatory feedback of glucocorticoid secretion
    Glucocorticoid receptor (GR), a ubiquitous transcriptional factor, regulates target gene expression upon activation by glucocorticoids, notably cortisol, ...
  20. [20]
    Epigenetic regulation of the expression of genes involved in steroid ...
    Here we review evidence for epigenetic regulation of enzymes, transcription factors, and nuclear receptors related to steroid biogenesis and action.
  21. [21]
    Steroidogenic factor-1 (SF-1, NR5A1) and human disease - PMC - NIH
    Steroidogenic factor-1 (SF-1, Ad4BP, encoded by NR5A1) is a key regulator of adrenal and reproductive development and function.
  22. [22]
    Role of DNA methylation in the tissue-specific expression ... - PubMed
    The expression of the CYP17A1 gene is tissue as well as species-specific. In contrast to humans, adrenals of rodents do not express the CYP17A1 gene and have ...
  23. [23]
    Genetics and Pathophysiology of Classic Congenital Adrenal ...
    Jan 21, 2025 · Approximately 90% to 95% of cases of CAH are caused by 21-hydroxylase deficiency (21OHD) caused by mutations in the CYP21A2 gene (1-3); the ...
  24. [24]
    21-Hydroxylase Deficiency - StatPearls - NCBI Bookshelf - NIH
    Jan 17, 2025 · Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency is an autosomal recessive disorder caused by a deficiency of 21-hydroxylase, ...
  25. [25]
    Congenital Adrenal Hyperplasia - StatPearls - NCBI Bookshelf - NIH
    Jan 27, 2025 · [5] Among Whites, the incidence is approximately 1 in 15,000 individuals. The global incidence of classic 21-OH–deficient CAH is estimated to ...Epidemiology · Pathophysiology · Treatment / Management · Prognosis
  26. [26]
    Partial Defect in the Cholesterol Side-Chain Cleavage Enzyme ... - NIH
    Genetic defects in P450scc cause a rare autosomal recessive disorder that is clinically indistinguishable from congenital lipoid adrenal hyperplasia (lipoid CAH) ...
  27. [27]
    Ambiguous Genitalia Due to 3β-Hydroxysteroid Dehydrogenase ...
    Jan 20, 2025 · In early steps of adrenal and gonadal steroidogenesis, 3βHSD2 converts precursors into metabolites of the mineralocorticoid, glucocorticoid, and ...
  28. [28]
    17-Hydroxylase Deficiency - StatPearls - NCBI Bookshelf - NIH
    Mar 17, 2025 · In general, 17-OH deficiency presents as sexual infantilism in individuals with both 46,XX and 46,XY chromosomes, along with hypertension and ...
  29. [29]
    Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency
    Feb 13, 2025 · 11β-hydroxylase (11β-OH) deficiency is the second most frequent cause of classic congenital adrenal hyperplasia (CAH) (5%-8% of cases).
  30. [30]
    AROMATASE DEFICIENCY - PMC - NIH
    For example, virilization was recognized as early as at 12 and as late as 30 weeks gestation in the mothers of fetuses with aromatase deficiency. (4, 14, 15) ...
  31. [31]
    Congenital Adrenal Hyperplasia - Endotext - NCBI Bookshelf - NIH
    Nov 3, 2022 · Congenital adrenal hyperplasia (CAH) is a term used to describe a group of genetically determined disorders of defective steroidogenesis.
  32. [32]
    Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency
    Sep 1, 2018 · In addition, approximately two-thirds of individuals with the classic form of CAH due to 11-beta-hydroxylase deficiency have high blood pressure ...
  33. [33]
    Genetics of Congenital Adrenal Hyperplasia - PMC - NIH
    This leads to defective cortisol synthesis, shunting of the accumulated steroid precursors through alternative pathways, and often adrenal gland hyperplasia.
  34. [34]
    Updates on the role of adrenal steroidogenesis inhibitors in ... - PMC
    Sep 6, 2016 · Ketoconazole inhibits key cytochrome P450 (CYP) enzymes involved in multiple steps of steroidogenesis in the adrenal cortex, including CYP17A1, ...
  35. [35]
    Update on Medical Treatment of Cushing's Syndrome - PMC - NIH
    Sep 15, 2025 · Ketoconazole inhibits multiple steroidogenic enzymes including CYP17A1, CYP11A1, and CYP11B1 [56]. It is administered orally at a dose of 400– ...
  36. [36]
    Preoperative treatment with metyrapone in patients with Cushing's ...
    This prospective pilot study demonstrated that metyrapone is effective in normalizing biochemical and clinical parameters in patients with CS due to adrenal ...
  37. [37]
    The development of abiraterone acetate for castration-resistant ...
    Regulatory authorities approved abiraterone acetate in 2011 after a survival benefit was demonstrated when given in combination with prednisone as compared with ...
  38. [38]
    Abiraterone (Zytiga), a Novel Agent for the Management of ... - PMC
    Abiraterone acetate (Zytiga, Janssen Biotech) is a new cytochrome P450 (CYP) 17 inhibitor that was approved by the FDA in 2011 in combination with prednisone ...
  39. [39]
    Aromatase Inhibitors - StatPearls - NCBI Bookshelf
    Jul 4, 2023 · Anastrozole is a medication used in the management and treatment of breast cancer. It is in the aromatase inhibitors class of drugs.
  40. [40]
    Emerging treatment for CAH - PMC - NIH
    Jun 1, 2023 · Gene therapy using an Adeno-Associated Virus (AAV) has been tested in an mouse model of 21OHD which carries a deletion of the active murine ...
  41. [41]
    AAV-delivered hepato-adrenal cooperativity in steroidogenesis - NIH
    Vectors based on adeno-associated virus are the leading system for direct in vivo gene delivery but have limitations in targeting replicating cell populations ...
  42. [42]
    Integration of Adjunctive Therapy for Congenital Adrenal Hyperplasia
    Jul 8, 2025 · An early phase clinical trial in adults for an adeno-associate virus 5 vector-based gene therapy [21] has recently been discontinued due to ...
  43. [43]
    Abiraterone-Induced Endocrinopathies - PMC - NIH
    Apr 13, 2023 · This inhibition leads to relative cortisol deficiency, impairing negative feedback on ACTH. Moreover, it also inhibits androgen production.
  44. [44]
    Cardiovascular Toxicities of Androgen Deprivation Therapy - PMC
    Apr 17, 2021 · The mechanism by which abiraterone causes hypertension is thought to be increased production of mineralocorticoids due to the lack of negative ...Table 3 · References And Recommended... · Papers Of Particular...Missing: hypoandrogenism | Show results with:hypoandrogenism
  45. [45]
    5α-Reductase Inhibitors - StatPearls - NCBI Bookshelf - NIH
    Jun 8, 2024 · The 5α-reductase inhibitors (finasteride and dutasteride) are effective treatments for both BPH and androgenic alopecia. Given the longer ...Continuing Education Activity · Indications · Mechanism of Action · Monitoring